Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are 50 years of age or older on the day of screening~* Have an understanding of the study, agree to its provisions, have the ability to adhere to the provisions of the study and give written informed consent prior to study entry~* If female and capable of bearing children,have a negative urine pregnancy test result within 24 hours prior to the vaccination on Study Day 0 and agree to employ adequate birth control measures.~Exclusion Criteria:~* History of severe allergic reaction or anaphylaxis to egg protein or any other component of the Vero cell-derived influenza vaccine or the egg-derived influenza vaccine~* Oral temperature of \>= 99.5°F (37.5°C) on the day of vaccination in this study (Note: Subjects meeting this exclusion criterion may be rescheduled for vaccination and study entry at a later date if certain requirements \[in the study protocol\] are met)~* Rash or dermatologic condition or tattoos which may interfere with injection site reaction rating~* Blood transfusion or immunoglobulins received within 90 days of study entry~* Live vaccine received within 4 weeks or inactivated vaccine or subunit vaccine received within 2 weeks of study entry~* Previous vaccination against influenza for the 2008/2009 northern hemisphere influenza season~* Functional or surgical asplenia (e.g. from a history of hemoglobinopathies, leukemias, or lymphomas)~* Diagnosed immunodeficiency as a result of a pathological condition~* Pharmacologically induced immunodeficiency as a result of prescribed administration of corticosteroids (e.g., any systemic administration of corticosteroids or an inhaled dose equivalent to 800 mg of beclomethasone dipropionate) or chemotherapeutics or as a result of radiation therapy or any other modality capable of altering normal immunologic response~* Known or suspected problem with drug or alcohol abuse~* Investigational drug received within 6 weeks prior to study entry or concurrent participating in a clinical study that includes the administration of an investigational product~* Subjects who are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, spouse/partner, siblings, parents) as well as employees of the investigator.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Vero cell-derived, trivalent, seasonal influenza vaccine
- 2 (Type: ACTIVE_COMPARATOR): Licensed egg-derived, trivalent seasonal influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).